I like:
- Increase of 121% on the March quarter 2019.
- Financial year-end Cash Receipts to June 2019 of $32,221,000 wereup 36% compared to the prior financial year (to June 2018).- This indicates that more EPP patients in Europe arereceiving treatment with SCENESSE® and we look forward to the time the same treatment access can be provided toAmerican EPP patients who have no current alternatives.”
- Net Cash from Operations was positive by $8,618,000 in the June quarter 2019. Net Cash from Operations for thetwelve months to 30 June 2019 was a positive $18,382,000 compared to a positive $11,693,000 in the same twelvemonth period to 30 June 2018.
- Increasing cash balance - Cash Balance as at 30 June2019 increased to $54,269,000, compared to $44,975,000 as at 31 March 2019 and $36,198,000 as at 30 June 2018.
Very positive outlook and building blocks foundation.
Well done!
Ann: Appendix 4C - quarterly, page-4
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.17 |
Change
-0.080(0.52%) |
Mkt cap ! $760.0M | |||
| Open | High | Low | Value | Volume |
| $15.38 | $15.56 | $15.02 | $774.6K | 50.94K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8378 | $15.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.26 | 808 | 2 |
View Market Depth
| Last trade - 16.10pm 04/07/2024 (20 minute delay) ? |
| CUV (ASX) Chart |